SG11201708470SA - Bromodomain inhibitor - Google Patents
Bromodomain inhibitorInfo
- Publication number
- SG11201708470SA SG11201708470SA SG11201708470SA SG11201708470SA SG11201708470SA SG 11201708470S A SG11201708470S A SG 11201708470SA SG 11201708470S A SG11201708470S A SG 11201708470SA SG 11201708470S A SG11201708470S A SG 11201708470SA SG 11201708470S A SG11201708470S A SG 11201708470SA
- Authority
- SG
- Singapore
- Prior art keywords
- bromodomain inhibitor
- bromodomain
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562148098P | 2015-04-15 | 2015-04-15 | |
PCT/US2016/027874 WO2016168682A2 (en) | 2015-04-15 | 2016-04-15 | Bromodomain inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708470SA true SG11201708470SA (en) | 2017-11-29 |
Family
ID=57126317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708470SA SG11201708470SA (en) | 2015-04-15 | 2016-04-15 | Bromodomain inhibitor |
Country Status (21)
Country | Link |
---|---|
US (3) | US9908885B2 (en) |
EP (2) | EP3831383A1 (en) |
JP (1) | JP6856543B2 (en) |
KR (1) | KR20170135938A (en) |
CN (1) | CN107635558A (en) |
AR (1) | AR104259A1 (en) |
AU (1) | AU2016249273B2 (en) |
CA (1) | CA2982588A1 (en) |
CL (1) | CL2017002606A1 (en) |
CO (1) | CO2017011484A2 (en) |
EA (1) | EA201792229A1 (en) |
EC (1) | ECSP17070706A (en) |
ES (1) | ES2868355T3 (en) |
HK (1) | HK1243326A1 (en) |
IL (1) | IL255006A0 (en) |
MX (1) | MX2017013207A (en) |
PE (1) | PE20180258A1 (en) |
PH (1) | PH12017501888A1 (en) |
SG (1) | SG11201708470SA (en) |
TW (1) | TW201643153A (en) |
WO (1) | WO2016168682A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR104259A1 (en) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | BROMODOMINUM INHIBITORS |
US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
JP2018527340A (en) | 2015-08-11 | 2018-09-20 | ネオメド インスティテュートNeomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
IL257340B2 (en) * | 2015-08-12 | 2023-10-01 | Neomed Inst | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN108314680A (en) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | One kind containing aromatic compound, preparation method, pharmaceutical composition and application |
TW202332436A (en) * | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | Therapeutic compounds |
CN107098844B (en) * | 2017-05-17 | 2019-07-30 | 许昌学院 | A kind of synthetic method for the acyl indol quinoline class compound that C-5 nitro replaces |
MX2020006612A (en) * | 2017-12-20 | 2020-11-09 | Betta Pharmaceuticals Co Ltd | Compound functioning as bromodomain protein inhibitor, and composition. |
CN112236172A (en) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | Methods and compounds for treating disorders |
CN108516973A (en) * | 2018-03-30 | 2018-09-11 | 广西师范大学 | 3- benzothiazoles -1- (3- dimethylaminos) propyl quinoline -4- ketone derivatives and its preparation method and application |
CA3107050A1 (en) * | 2018-07-23 | 2020-01-30 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
EP4364798A3 (en) | 2018-10-05 | 2024-06-19 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
US20220098190A1 (en) * | 2019-01-29 | 2022-03-31 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
WO2020160193A2 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN113874016A (en) * | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | Compound and use thereof |
JP2022053557A (en) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | Pyridone derivative |
CA3137870A1 (en) * | 2019-04-24 | 2020-10-29 | Convergene, Llc | Small molecule bromodomain inhibitors and uses thereof |
CN112174945B (en) * | 2019-07-02 | 2022-06-07 | 四川大学 | Indazole compound with anticancer effect and preparation method and application thereof |
BR112021026668A2 (en) * | 2019-07-02 | 2022-02-15 | Nuvation Bio Inc | Heterocyclic compounds as beta inhibitors |
US20220289711A1 (en) * | 2019-07-31 | 2022-09-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
TW202140485A (en) | 2020-01-29 | 2021-11-01 | 美商福宏治療公司 | Compounds and uses thereof |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
JP2023536139A (en) * | 2020-07-29 | 2023-08-23 | フォグホーン セラピューティクス インコーポレイテッド | Compounds and uses thereof |
US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
CN114014842B (en) * | 2021-11-04 | 2024-03-01 | 中国药科大学 | Heterocyclic ketone compound and composition thereof, and preparation method and application thereof |
WO2023090859A1 (en) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | Method for preparing isoxazole derivative, and novel intermediate therefor |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1349418A (en) * | 1919-08-05 | 1920-08-10 | George F Flynn | Motor-support |
US3590036A (en) * | 1968-11-18 | 1971-06-29 | George Y Lesher | Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof |
DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
GB1322318A (en) * | 1971-05-19 | 1973-07-04 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and esters |
BE786028A (en) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-DIHYDRO-OXO-IMIDAZO (1,2-A) -PYRIMIDINES, THEIR ADDITIONAL SALTS WITH ACIDS AND METHODS FOR MANUFACTURING THEM |
DE2356005A1 (en) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Analgesic 7-amino-imidazo (1,2-a) pyrimidines - pprepd. by condensation of substd. 2-amino imidazolin-(2) and substd. cyano fatty acid esters |
AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
DE60137426D1 (en) * | 2000-06-12 | 2009-03-05 | Eisai R&D Man Co Ltd | 1,2-Dihydropyridine compounds, process for their preparation and their use |
GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
AU2003263455A1 (en) | 2002-09-26 | 2004-04-19 | Pfizer Inc. | Pyrazole amides for treating hiv infections |
JP2005089352A (en) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | NEW IMIDAZO[1,5-a]PYRAZINE DERIVATIVE, MEDICINE COMPOSITION CONTAINING THE SAME AND THEIR USE |
US7763614B2 (en) * | 2003-09-23 | 2010-07-27 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
KR100703068B1 (en) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them |
TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
WO2005095384A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR100781704B1 (en) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
MX2008001053A (en) | 2005-07-26 | 2008-03-19 | Sanofi Aventis | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors. |
CN101228132B (en) | 2005-07-26 | 2012-10-10 | 塞诺菲-安万特股份有限公司 | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
JP2009531314A (en) | 2006-03-10 | 2009-09-03 | ニューロジェン・コーポレーション | Piperazinyloxoalkyltetrahydroisoquinolines and related analogs |
GB0612428D0 (en) * | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
WO2008077551A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone derivatives |
MX2009005825A (en) | 2006-12-27 | 2009-06-16 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase. |
SI2102164T1 (en) | 2006-12-27 | 2011-03-31 | Sanofi Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
ES2390004T3 (en) | 2008-01-30 | 2012-11-05 | Cephalon, Inc. | Substituted spirocyclic piperidine derivatives as histamine 3 (H3) receptor ligands |
EP2313408B1 (en) | 2008-06-25 | 2012-07-11 | Bristol-Myers Squibb Company | Diketopiperidine derivatives as hiv attachment inhibitors |
WO2010039186A2 (en) * | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
WO2010071819A1 (en) * | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CN102665718B (en) | 2009-10-06 | 2016-03-09 | 米伦纽姆医药公司 | Can be used as the heterocyclic compound of PDK1 inhibitor |
CN102753545A (en) * | 2009-12-15 | 2012-10-24 | 盐野义制药株式会社 | Oxadiazole derivative having endothelial lipase inhibitory activity |
EA201300052A1 (en) | 2010-06-28 | 2013-06-28 | Мерк Патент Гмбх | [1,8] NAPHTHYRID DERIVATIVES |
JPWO2012086735A1 (en) * | 2010-12-22 | 2014-06-05 | 大正製薬株式会社 | Fused heterocyclic compounds |
RU2017140639A (en) * | 2011-05-23 | 2019-02-12 | Элан Фармасьютикалз, Инк. | KINASE LRRK2 KINASE ACTIVITY INHIBITORS |
RU2477723C2 (en) * | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Protein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical composition |
CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
KR20140105445A (en) | 2011-10-31 | 2014-09-01 | 제논 파마슈티칼스 인크. | Biaryl ether sulfonamides and their use as therapeutic agents |
CN103183675A (en) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | Phosphodiesterase-4 inhibitor |
WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
WO2013186229A1 (en) * | 2012-06-11 | 2013-12-19 | Ucb Pharma S.A. | Tnf -alpha modulating benzimidazoles |
JP2014024838A (en) * | 2012-06-21 | 2014-02-06 | Taisho Pharmaceutical Co Ltd | Hypoglycemic agonist containing condensed heterocyclic compound as active ingredient |
WO2014015088A1 (en) * | 2012-07-19 | 2014-01-23 | Bristol-Myers Squibb Company | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014109414A1 (en) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | Nitrogen-containing heterocylic compound or salt thereof |
JP6401773B2 (en) * | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | BET bromodomain inhibitor and therapeutic method using the same |
SG11201506687RA (en) * | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
US9890166B2 (en) * | 2013-05-27 | 2018-02-13 | Novartis Ag | Imidazopyrrolidine derivatives and their use in the treatment of disease |
JP6461118B2 (en) * | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
WO2014205594A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
LT3013337T (en) * | 2013-06-26 | 2019-01-10 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
CN108558889B (en) * | 2013-10-18 | 2021-11-05 | 赛尔基因昆蒂赛尔研究公司 | Bromodomain inhibitors |
WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
BR112016012243A2 (en) | 2013-12-09 | 2017-08-08 | Ucb Biopharma Sprl | IMIDAZOPIRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY |
WO2015105749A1 (en) * | 2014-01-07 | 2015-07-16 | Bristol-Myers Squibb Company | Sulfone amide linked benzothiazole inhibitors of endothelial lipase |
EP3096761A1 (en) | 2014-01-24 | 2016-11-30 | Confluence Life Sciences, Inc. | Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases |
ES2784846T3 (en) * | 2014-04-23 | 2020-10-01 | Incyte Corp | 1H-pyrrolo [2,3-C] pyridin-7 (6H) -ones and pyrazolo [3,4-C] pyridin-7 (6H) -ones as BET protein inhibitors |
MA40943A (en) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
MA40940A (en) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS |
WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
AR104259A1 (en) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | BROMODOMINUM INHIBITORS |
TW201642860A (en) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | Bromodomain inhibitor |
-
2016
- 2016-04-14 AR ARP160101014A patent/AR104259A1/en unknown
- 2016-04-15 JP JP2017553414A patent/JP6856543B2/en active Active
- 2016-04-15 CA CA2982588A patent/CA2982588A1/en active Pending
- 2016-04-15 PE PE2017002197A patent/PE20180258A1/en not_active Application Discontinuation
- 2016-04-15 SG SG11201708470SA patent/SG11201708470SA/en unknown
- 2016-04-15 US US15/130,503 patent/US9908885B2/en active Active
- 2016-04-15 EA EA201792229A patent/EA201792229A1/en unknown
- 2016-04-15 TW TW105111879A patent/TW201643153A/en unknown
- 2016-04-15 MX MX2017013207A patent/MX2017013207A/en unknown
- 2016-04-15 AU AU2016249273A patent/AU2016249273B2/en active Active
- 2016-04-15 WO PCT/US2016/027874 patent/WO2016168682A2/en active Application Filing
- 2016-04-15 CN CN201680034663.2A patent/CN107635558A/en active Pending
- 2016-04-15 ES ES16780891T patent/ES2868355T3/en active Active
- 2016-04-15 EP EP20215944.8A patent/EP3831383A1/en active Pending
- 2016-04-15 EP EP16780891.4A patent/EP3283077B1/en active Active
- 2016-04-15 KR KR1020177032364A patent/KR20170135938A/en unknown
-
2017
- 2017-10-13 CL CL2017002606A patent/CL2017002606A1/en unknown
- 2017-10-15 IL IL255006A patent/IL255006A0/en unknown
- 2017-10-18 PH PH12017501888A patent/PH12017501888A1/en unknown
- 2017-10-24 EC ECIEPI201770706A patent/ECSP17070706A/en unknown
- 2017-11-08 CO CONC2017/0011484A patent/CO2017011484A2/en unknown
-
2018
- 2018-01-12 US US15/870,557 patent/US10494371B2/en active Active
- 2018-02-27 HK HK18102785.5A patent/HK1243326A1/en unknown
-
2019
- 2019-11-04 US US16/673,839 patent/US10807982B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9908885B2 (en) | 2018-03-06 |
CO2017011484A2 (en) | 2018-01-31 |
HK1243326A1 (en) | 2018-07-13 |
WO2016168682A3 (en) | 2016-12-08 |
EP3283077B1 (en) | 2021-03-10 |
IL255006A0 (en) | 2017-12-31 |
MX2017013207A (en) | 2018-02-19 |
AU2016249273A1 (en) | 2017-11-09 |
US10494371B2 (en) | 2019-12-03 |
PE20180258A1 (en) | 2018-02-05 |
US20180134710A1 (en) | 2018-05-17 |
PH12017501888A1 (en) | 2018-03-05 |
JP2018511626A (en) | 2018-04-26 |
EP3283077A4 (en) | 2019-01-23 |
EA201792229A1 (en) | 2018-05-31 |
EP3831383A1 (en) | 2021-06-09 |
AU2016249273B2 (en) | 2020-07-09 |
WO2016168682A2 (en) | 2016-10-20 |
ECSP17070706A (en) | 2017-12-01 |
CA2982588A1 (en) | 2016-10-20 |
US20170050968A1 (en) | 2017-02-23 |
US20200071332A1 (en) | 2020-03-05 |
JP6856543B2 (en) | 2021-04-07 |
US10807982B2 (en) | 2020-10-20 |
CN107635558A (en) | 2018-01-26 |
TW201643153A (en) | 2016-12-16 |
ES2868355T3 (en) | 2021-10-21 |
AR104259A1 (en) | 2017-07-05 |
EP3283077A2 (en) | 2018-02-21 |
CL2017002606A1 (en) | 2018-05-18 |
KR20170135938A (en) | 2017-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243326A1 (en) | Bromodomain inhibitors | |
ME03759B (en) | Bromodomain inhibitors | |
HK1243415A1 (en) | Bromodomain inhibitors | |
DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
HK1243948A1 (en) | Bromodomain inhibitor | |
GB201513481D0 (en) | Inhibitor compounds | |
IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
GB201505658D0 (en) | Inhibitor compounds | |
GB201501004D0 (en) | Inhibitors | |
GB201517368D0 (en) | Value | |
GB201612860D0 (en) | Inhibitors | |
AU361999S (en) | Ballustrade | |
DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
GB201513637D0 (en) | Pooppot | |
GB201511951D0 (en) | An eyeguard | |
GB201520949D0 (en) | Inhibitors | |
ZA201807614B (en) | Bromodomain inhibitors | |
IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
AU5511P (en) | PTK647 Epichloe coenophiala | |
GB201522453D0 (en) | Inhibitor compounds | |
AU366552S (en) | Nutblock | |
AU367131S (en) | USB-charger | |
GB201516350D0 (en) | Anywhere bankstick | |
GB201516257D0 (en) | Setouting application |